OUR
PIPELINE
CTXA: MMP2 INHIBITOR
FOR CANCER DIAGNOSIS
AND TREATMENT
FOR CANCER DIAGNOSIS
AND TREATMENT
DEVELOPMENT OF A NEW ANTITUMOR INHIBITOR FROM SCORPION VENOM TARGETING THE HUMAN PLASMA TISSUE MATRIX METALLOPROTEINASE-2.
The purpose of this research is to develop new molecules for the therapy and diagnostics of MMP-2 expressing tumors such as glioblastoma. The goal of the 3-year project has been met: we developed a patentable 'lead compound' group that is superior to the start compound chlorotoxin in that it can target malignant tumor cells more efficiently and selectively than chlorotoxin does. We have filed a patent application for these compounds.Our lead compound can also be used as a targeting molecule in chimeric antigen receptor (CAR) T-cell therapy.
On 15.11.2017, this project received a grant funding of HUF 496,355,200 from the National Office for Research, Development and Innovation under the grant ID KFI_16-2017-0524. With the funding intensity being 70,77%, the total cost of e project is HUF 701,380,000.
Kv1.3: SELECTIVE POTASSIUM
CHANNEL INHIBITOR
FOR AUTOIMMUNE
DISEASES
CHANNEL INHIBITOR
FOR AUTOIMMUNE
DISEASES
DEVELOPMENT OF NEW Kv1.3 CHANNEL-SPECIFIC ANTI-AUTOIMMUNE MECHANISMS
Chronic inflammatory and autoimmune diseases place a heavy burden on society. Sustained activation of effector memory T cells (TEM) plays a key role in the development of autoimmune diseases. TEM cells but no other immune cells excessively rely on KCNA3 (Kv1.3) potassium channels for persistent activation. Therefore, a drug that selectively inhibits KCNA3 (Kv1.3) but no other potassium channels, could be used to treat chronic inflammatory and autoimmune diseases effectively and with a better safety profile compared to currently used immunosuppressant therapies.
Our goal is to develop such an inhibitor by directing the evolution of animal toxin libraries created by segment shuffling.
On 12.12.2019, this project received a grant funding of 322 219 918 HUF from the National Office for Research, Development and Innovation under the grant ID 2019-1.1.1-MARKET-KFI-2019-00127. With the funding intensity being 52.65%, the total cost of the project is HUF 612 051 295.
Combi-X: FIXED DOSE
COMBINATION (FDC)
PRODUCT FOR MIGRAINE
PROPHYLAXIS
COMBINATION (FDC)
PRODUCT FOR MIGRAINE
PROPHYLAXIS
DEVELOPMENT OF A FIXED-COMBINATION DRUG FOR MIGRAINE PROPHYLAXIS
Migraine is a debilitating disease characterized by recurring attacks of headaches affecting many people (17% of women, 6% of men) and can cause severe temporary incapacity for work. Approximately 38% of migraine patients have more than 2 attacks a month, which experts say would warrant prophylaxis, but these conditions are undertreated. The Combi-X project aims to develop a fixed-combination product comprising two drugs with various mechanisms. This new combination also represents the repurposing of drugs with well-known safety and tolerability profiles originally aimed for other indications. The novel drug combination is expected to provide better and more cost-effective prophylactic treatment for migraineurs than currently available drugs (e.g., topiramate, beta-blockers, CGRP inhibitors) and also targets currently therapy-resistant cases.On 22.07.2021, this project received a grant funding of 101 837 282 HUF from the National Office for Research, Development and Innovation under the grant ID 2020-1.1.2-MARKET-KFI-2021-00207. With the funding intensity being 56.09%, the total cost of the project is HUF 181 561 564.
DREADD: DESIGNER RECEPTOR EXCLUSIVELY ACTIVATED BY DESIGNER DRUG
DEVELOPMENT OF A MODIFIED RECEPTOR THAT ALLOWS PHARMACEUTICAL TARGETING OF SPECIFIC NEURONAL POPULATIONS
DREADDs are exclusively activated by their pharmaceutical ligand (actuator). CNS-delivered artificial DREADDs have no physiological effects without their actuator, offering a flexible and adaptive control of the timing and intensity of the effect. This technique can be employed to develop a safe, adjustable alternative of current neurosurgery techniques, such as deep brain stimulation and local lesion. Moreover, molecular targeting solutions (e.g. promoters) allows disctinction between neuronal populations not only based on their localization, but also based on their neurochemical attributes. On the long run, non-surgical delivery may provide additional benefits to this platform.
↑
